Novartis withdraws marketing application for Ruvise
LONDON (Reuters) - Swiss drugmaker Novartis has withdrawn a marketing application for its drug Ruvise, designed to treat arterial hypertension, the European Medicines Agency (EMA) said on Thursday.
The drug, known generically imatinib mesilate, was intended for use in adults as add-on therapy for the treatment of pulmonary arterial hypertension (PAH), the drug regulator said in a statement.
EMA reported that Novartis had said that the withdrawal was because it requires additional data to address the regulator's questions relating to its benefit-risk assessment.
The data would not be available within the timeframe allowed in the centralized procedure, it said.
(Reporting by Kate Kelland; Editing by David Goodman)
- Australia leads southern search for missing Malaysian plane |
- Crimeans vote over 90 percent to quit Ukraine for Russia |
- France bans Monsanto GM maize ahead of sowing season
- Ukraine, Russia agree Crimea truce until March 21-Ukraine minister
- Shares hit as Crimea vote to spur sanctions against Moscow |